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Detecting and monitoring arrhythmia
recurrence following catheter
ablation of atrial fibrillation
Olujimi A. Ajijola *, Noel G. Boyle and Kalyanam Shivkumar
UCLA Cardiac Arrhythmia Center, UCLA Health System/David Geffen School of Medicine at UCLA, University of California,
Los Angeles, Los Angeles, CA, USA
Atrial fibrillation (AF) is the most common arrhythmia prompting clinical presentation, is
associated with significant morbidity and mortality. The incidence and prevalence of this
arrhythmia is expected to grow significantly in the coming decades. Of the available
pharmacologic and non-pharmacologic treatment options, the fastest growing and most
intensely studied is catheter-based ablation therapy for AF. Given the varying success
rates for AF ablation, the increasingly complex factors that need to be taken into account
when deciding to proceed with ablation, as well as varying definitions of procedural
success, accurate detection of arrhythmia recurrence and its burden is of significance.
Detecting and monitoring AF recurrence following catheter ablation is therefore an
important consideration. Multiple studies have demonstrated the close relationship
between the intensity of rhythm monitoring with wearable ambulatory cardiac monitors,
or implantable cardiac rhythmmonitors and the detection of arrhythmia recurrence. Other
studies have employed algorithms dependent on intensive monitoring and arrhythmia
detection in the decision tree on whether to proceed with repeat ablation or medical
therapy. In this review, we discuss these considerations, types of monitoring devices,
and implications for monitoring AF recurrence following catheter ablation.
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Introduction
Atrial fibrillation (AF) is the most common arrhythmia prompting presentation for clinical care
(January et al., 2014). In patients over 40 years of age, the prevalence of AF is 2.3%; 6% in patients
65 years and over (Feinberg et al., 1995); and rising to 10% in those greater than 80 years (Lloyd-
Jones et al., 2010) with these values expected to rise significantly in the coming decades (Go et al.,
2001). Although, AF has been associated with increasedmortality in the long-term (Benjamin et al.,
1998), the most devastating non-fatal complication of AF remains cerebrovascular accidents (CVA)
(Flegel et al., 1987; Wolf et al., 1991). To this end, the importance of anticoagulation in risk reduc-
tion of CVA, is strongly emphasized, and widely recognized (Gage et al., 2001; Wyse et al., 2002;
January et al., 2014). Despite AF being one of the earliest recognized arrhythmias, treatment options
for AF remain limited.
In the past two decades, few new pharmacologic options have become available, all with lim-
ited efficacy and potential toxicity. Following the recognition of pulmonary vein triggers (Hais-
saguerre et al., 1998), catheter ablation of AF continues to gain acceptance as a viable treatment
option (Tung et al., 2012), with its main indication being the elimination of symptomatic AF,
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when pharmacologic agents are contraindicated or have failed
(January et al., 2014).
As the decision to proceed with AF ablation depends on a
number of factors including age, comorbidities, patient prefer-
ence, contraindications to anticoagulation, and left atrial dimen-
sions/fibrosis, the determination of success following ablation
similarly depends on similar factors (Kircher et al., 2012), since
AF is typically not considered cured following initial catheter
ablation. As a result, the methods employed in detecting and
monitoring AF recurrence following catheter ablation have a sig-
nificant impact on the determination of “success.” Measures used
to define success include complete elimination or reduction of AF
burden, and the elimination or reduction of symptoms. Without
adequate monitoring, the complete absence of symptoms may
not equate absence of AF, and further, evaluating reduction or
elimination of AF is not possible with incomplete monitoring.
Objectives of Monitoring after Atrial Fibrillation
Ablation
Success rates for catheter ablation of AF, defined typically as free-
dom from AF, have ranged from 60 to 90%, depending on the
study, and the number of procedures performed (January et al.,
2014). At present, the indication for catheter ablation of AF is
symptom control in patients for whom pharmacologic options
are contraindicated or have failed (Fuster et al., 2011; January
et al., 2014). As such, it stands to reason that patient-reported
symptoms should be the primary factor used for determination
of outcome/success following ablation. This would certainly sim-
plify follow up after catheter ablation for AF. In addition, the
indication for therapeutic anticoagulation is individualized, and
is based on CVA risk factors, most commonly, the CHADS2
(Gage et al., 2001) and/or CHADS2-VASc (Camm et al., 2010)
scores, and is independent of the outcome following catheter
ablation of AF.
However, a number of important considerations should be
entertained. First, symptom reporting by patients is known to
be an inaccurate estimation of true AF burden, even in patients
who have experienced symptomatic episodes of AF. In a study of
patients with paroxysmal or persistent AF, with implanted pace-
makers for other indications, AF was detected in 88% of patients
over 19 ± 11 months of follow up, with over a third of patients
with long duration episodes of AF (>48 h) being asymptomatic
(Israel et al., 2004). In the same study, the authors also observed
poor correlation between reported symptoms and AF, with up to
40% of patients reporting symptoms consistent with AF, but no
such documentation on device interrogations. In another study,
up to 45% of patients with AF recurrences documented by an
implanted loop recorder, reported no symptoms of AF (Tondo
et al., 2013). Further, following catheter ablation for AF, the per-
ception of symptoms may also change, either due to modulation
of atrial tissue and/or innervation, or a placebo effect. In a study
tracking the burden of silent AF with continuous 7-day Holter
monitoring before and serially following ablation for AF, the per-
centage of silent episodes of AF increased significantly at 3, 6, and
12 months following catheter ablation (Hindricks et al., 2005).
Intensive monitoring early (60 days) after AF ablation may be
useful in identifying patients at risk of recurrence in the long-
term (12-months) (Pokushalov et al., 2012), such that targeted
strategies for management of such patients can be applied early,
and potentially before symptoms develop. Pokushalov and col-
leagues employed such a strategy, and identified patients with
recurrences at 3 months following AF ablation, randomizing
them to medical therapy, or if possible triggers were identified
with an implantable monitor, to repeat ablation (Pokushalov
et al., 2011). The rate of AF recurrence at 12 months was signif-
icantly greater in patients randomized to medical therapy than
those randomized to repeat ablation.
Clinical factors associated with arrhythmia recurrences may
be related to the length of time post-ablation, and hence dura-
tion of follow up. In one study (Kim et al., 2014) total ablation
time correlated with recurrences at 6 months. However, at 1- and
2-year follow up, other factors such as the presence of hyperten-
sion, left atrial size, left atrial appendage (LAA) emptying fraction
under 20%, and decreased LAA emptying velocity were corre-
lated with AF recurrence. This suggests that follow upmonitoring
and arrhythmia detection for certain patients may need to be
extended past the typical 3-, 6-, and 12-month periods.
Lastly, given the variable reported success rates following
catheter ablation for AF, continued research on technologies and
strategies to improve AF ablation will rely heavily on accurate
demonstration of no AF recurrence. It is well recognized that
for patients with asymptomatic AF, the intensity of follow up is
correlated with the incidence of recurrences (Roche et al., 2002).
As patient symptoms may change following ablation, identifica-
tion of such episodes, necessitating continued AAD use or other
management strategies would be important. Accurate documen-
tation of true AF burden following catheter ablation may also
be very useful in discussions with patients. Demonstrating the
impact of AF ablation or lack thereof may be useful in provid-
ing objective data to patients, and reported symptoms with AF
recurrences. Such data may help patients participate in clinical
decision-making regarding their arrhythmia.
Atrial Arrhythmia Recurrences Following
Catheter Ablation of Atrial Fibrillation
Although AF recurrences following catheter ablation are most
commonly due to PV reconnection (Callans et al., 2004) or
incomplete ablation lines (Del Greco et al., 2008), other atrial
arrhythmias may occur after AF ablation. Focal and micro-
reentrant atrial tachycardias, macro-reentrant atrial flutters, and
premature ventricular contractions have been reported follow-
ing catheter ablation (Gerstenfeld et al., 2004; Mesas et al., 2004;
Deisenhofer et al., 2006; Fiala et al., 2007; Sawhney et al., 2011;
Patel et al., 2014). These arrhythmias are often complex due atrial
scars created by prior ablation, and may involve multiple macro-
reentrant circuits. Ablation of the critical isthmus of one circuit
may shift the arrhythmia to another circuit. Of particular impor-
tance is the characterization of the recurrent arrhythmia, as this
is useful in pre-procedural planning. Patients may also have more
than one arrhythmia induced at electrophysiology study, and as
a result, the determination of the clinical arrhythmia is crucial.
Focal atrial tachycardias from pulmonary veins or other regions
may be differentiated from macro-reentrant tachycardias with
monitoring (Gerstenfeld et al., 2007; Chang et al., 2011; Wasmer
et al., 2012), and a variety of approaches may be devised prior to
electrophysiology study.
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Existing Devices for Rhythm Monitoring
There are a variety of different cardiac rhythm monitoring
devices available (Table 1) clinically for patient use today. They
however fall into two major subtypes: wearable non-invasive and
implanted devices.
Wearable Cardiac Rhythm Monitors
Although multiple wearable devices exist, they can be classi-
fied by length of time for which they are worn, the number of
leads, and whether real-time monitoring is performed or not.
Holter monitors can be typically worn for 24 h, 7 or 30 days or
for any time interval provided the device is capable of record-
ing for that length of time. Advantages and limitations are spe-
cific to each device selected (Table 2), with the relative ease
of use of short-term devices counterbalanced by low sensitivity
and specificity of such devices for arrhythmia detection. Devices
worn for longer periods of time, 7–30 days have the advantage
of being more sensitive and specific in determining arrhyth-
mia recurrence, however, these gains are countered by relative
discomfort experienced by patients, with increasing noncompli-
ance with wearing such devices continuously. A number of stud-
ies have assessed the diagnostic utility of different durations of
monitoring (Kottkamp et al., 2004; Senatore et al., 2005; Dagres
et al., 2010). Kottkamp et al. demonstrated that compared to the
conventional 24-h monitoring, 7-day ECG recordings detected
more arrhythmias in the early post-ablation period, and at 6
and 12 months. The yield of a longer monitoring period was
underscored by the study from Senatore et al., where daily and
symptom-triggered recordings transmitted trans-telephonically
(for 3 months beginning 1 month post-ablation) was compared
TABLE 1 | Types of cardiac monitoring devices.
Holter Monitor (wired and wireless devices available)
Event monitor
Presymptom memory loop recorders
Autodetect recorders
Implantable loop recorders
Pacemakers or defibrillators (already implanted)
Source: National Institutes of Health—Public Health Information. Listed in the table are
the different types of cardiac monitoring devices available for clinical use.
TABLE 2 | Comparison of monitoring devices for atrial fibrillation.
Wearable monitors Implantable monitors
Easily available Prolonged monitoring period
Advantages Inexpensive Reliable
Typically well-tolerated
Limited monitoring period Requires invasive procedure
for implantation
Disadvantages Low patient tolerance More expensive
Potential for noncompliance Infection risk
Listed are the advantages and disadvantages to the major subtypes of cardiac monitoring
devices available for clinical use.
to 24-h Holter and ECG recordings. In this study, arrhythmia
detection by trans-telephonic monitoring was twice that in con-
ventional Holter and ECG recordings. Dagres and colleagues
evaluated over 200 consecutive patients with 7-day Holter moni-
toring 6 months post-ablation. By evaluating the data collected at
increasing 24-h intervals, they showed that any Holter monitor-
ing period of less than 5 days would have significantly underesti-
mated the rates of recurrence.
Overcoming some of the limitations of Holter recordings, the
ZIO Patch system offers improved ease of use for patients, as
it is a wearable adhesive patch without interconnecting wires,
and can provide continuous monitoring for 14 days. Addition-
ally patients can shower with this system in place, but not with
the standard Holter system. In a small study comparing 14-day
ZIO Patch to a 24-h Holter, not surprisingly, the patch system
performed better at detecting arrhythmias (Barrett et al., 2014).
Other patch devices and electrodes are currently under devel-
opment (Lobodzinski, 2013), with the goal of miniaturizing the
devices and electrodes used for monitoring.
Implantable Cardiac Rhythm Monitors
Subcutaneous implantable cardiac rhythm monitors (ICRMs)
improve the sensitivity and specificity of cardiac rhythm moni-
toring, and overcome the limitation on patient non-compliance
seen with long-term wearable devices (Table 2). If placed so that
there is no interference from myopotentials, or movement of the
monitor within the device pocket, implanted monitors with AF
recognition algorithms are a powerful means of rhythm moni-
toring. In the XPECT trial, Hindricks et al. demonstrated that
compared to a specialized Holter recording, ICRMs exhibited
a sensitivity, specificity, positive predictive value, and negative
predictive value of 96.1, 85.4, 79.3, and 97.4%, respectively, for
identifying patients with any AF (Hindricks et al., 2010). How-
ever, implanted monitors are limited to only a small subset of
patients who may have other indications for intensive monitor-
ing, and have not been widely adopted for routine clinical use
following AF ablation. Outside of research studies, the role that
routine use of ICRMsmay play in post-AF ablation rhythmman-
agement remains unclear. The recently introduced Medtronic
Reveal LINQmay offer additional advantages due to its small size,
reduced procedural requirements for implantation, and smaller
size on the chest wall. Rather than a small incision and blunt dis-
section to create a pocket for the device, the LINQ is implanted
by a syringe injector with an incision <1 cm. Whether the avail-
ability of such a small device and the ease of implantation will
increase its use for monitoring of arrhythmias following catheter
ablation outside of research studies remains to be seen. Apart
from subcutaneous ICRMs, implanted permanent pacemakers
(PPMs) or cardioverter-defibrillators (ICDs) with an atrial lead
can also be used for monitoring recurrence following AF abla-
tion. Due to larger memory capabilities, these devices can store
more details and for longer periods than standard subcutaneous
ICRMs. Another added advantage is the ability to assess the cycle
lengths of AF in greater detail, as well as improved discrimina-
tion of AF from other atrial arrhythmias that may mimic AF.
These devices however, have a focused applicability for patients
with AF. Only patients with AF and an additional indication for
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pacing such as sick sinus syndrome in the case of PPMs, and
cardiomyopathy or ventricular arrhythmias in the case of ICDs,
will qualify for these devices.
Our Approach to Monitoring Recurrence
Following Catheter Ablation of Atrial Fibrillation
Routine monitoring following catheter ablation of AF is usually
at the discretion of the physician and/or institution. At our cen-
ter, patients typically undergo 7- to 14-day ambulatory telemetry
monitoring during the initial evaluation and prior to catheter
ablation to document AF burden. In addition to quantifying
the severity of AF and correlation with symptoms, identifica-
tion of other arrhythmias (narrow complex tachycardias such as
atrioventricular nodal reentrant, atrioventricular reciprocating,
and focal or macro-reentrant atrial tachycardias or flutters) that
degenerate into AF may occur, necessitating a different ablation
strategy. Following catheter ablation, patients are seen for a 30-
day outpatient follow up visit during which a 12-lead ECG is per-
formed. At 3, 6, and 12 months post-ablation, patients undergo
7-day Holter monitoring to assess AF recurrence, burden, identi-
fication of other arrhythmias, and correlation with any reported
symptoms. In patients with implanted devices (pacemakers and
defibrillators with an atrial lead, or loop recorders) device inter-
rogation is typically performed to assess for atrial high rate
episodes, device mode switches, and overall atrial tachycardia/AF
burden.
Implications for Monitoring AF Recurrences
The role of implanted monitoring devices strictly for monitor-
ing recurrences following catheter ablation is unclear at present.
Outside of research studies, routine use of ICRMs has not been
reported in the literature. Routine clinical used of extended
Holter monitoring for 7 days (at least 5 days) is supported
by multiple clinical studies (Kottkamp et al., 2004; Piorkowski
et al., 2005; Senatore et al., 2005; Dagres et al., 2010). A recent
provocative study (Charitos et al., 2014) used computer simu-
lations to predict the diagnostic utility of various durations of
Holter monitoring, and the frequency with which they would
need to be performed in a 12-year period. The authors reviewed
the rhythm histories from 647 patients with AF and ICRMs, and
used computational simulations to assess arrhythmia detection
for 24-h, 7-, 14-, and 30-day monitors. The authors observed
that the frequency with which any monitor needed to be per-
formed depended on the rate and temporal aggregation of AF
recurrences as well as the duration of monitoring, in the popu-
lation of interest. They found that to achieve a >95% sensitiv-
ity in detecting AF recurrences, more frequent monitoring with
shorter duration monitors (greater than twelve 24-h; six 7-day;
four 14-day; and three 30-day monitors) were needed. When the
sensitivity over the monitored time was assessed, more frequent
but shorter monitoring durations were more time effective. The
implication of this study is that patients are under-monitored for
arrhythmia recurrence after catheter ablation, if they do not have
an implanted device.
Conclusion
The population burden of AF is expected to increase dramat-
ically in the next decades. It will become increasingly impor-
tant to adequately assess the success rates of non-pharmacologic
and pharmacologic therapies to improve patient care. With the
advent of smaller wearable monitoring devices, and with sig-
nificant improvements in the size, implantation procedures for
ICRMs, the landscape of monitoring AF recurrence following not
only catheter ablation procedures, but also with pharmacologic
therapies will likely significantly change.
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